2021至2023年塞内加尔东南部抗疟药耐药相关分子标志物监测
该研究在塞内加尔Kédougou地区对2021、2022和2023年确诊的恶性疟原虫感染患者静脉血样本采用多重扩增子深度测序,分析PfKelch13、Pfmdr1、Pfcrt、dhfr和dhps基因多态性。结果显示未发现PfKelch13非 synonymous突变,Pfcrt突变占45%(主要为K76T 44%和I356T 36%),Pfmdr-1优势等位基因为Y184F(62%),dhfr/dhps六重突变体占10%。作者认为ACT疗效未受损,但需临床结局研究确认,并需持续监测抗疟药耐药。
要点
- 未检测到PfKelch13非 synonymous突变,提示青蒿素联合疗法疗效未受损。
- Pfcrt突变占45%,主要为K76T(44%)和I356T(36%),可能源于既往氯喹使用并缓慢下降。
- dhfr/dhps六重突变体51I/59R/108N+436A/437G/613S占10%,需监测磺胺多辛-乙胺嘧啶耐药及581G出现。
核心结论
- 未发现PfKelch13突变体提示ACT疗效仍未受损,但需临床结局研究确认。
- Pfcrt和Pfmdr-1分析显示氯喹耐药等位基因可能因既往氯喹使用而缓慢下降。
- 检出dhfr/dhps六重突变体凸显监测磺胺多辛-乙胺嘧啶耐药及581G出现的必要性。
- 塞内加尔需继续开展抗疟药耐药监测。
研究设计与样本
- 在塞内加尔Kédougou采集2021、2022和2023年三年期间确诊恶性疟原虫感染患者的静脉血样本。
- 提取寄生虫DNA,采用多重扩增子深度测序研究基因多态性。
主要发现
- PfKelch13分析未发现任何非 synonymous突变。
- Pfcrt突变存在于45%的样本中,主要为K76T(44%)和I356T(36%)。
- Pfmdr-1优势等位基因为Y184F(62%)。
- dhfr/dhps六重突变体51I/59R/108N+436A/437G/613S在10%的样本中观察到。
关键数值与推荐
- PfKelch13非 synonymous突变:0%。
- Pfcrt突变:45%;K76T:44%;I356T:36%。
- Pfmdr-1 Y184F等位基因:62%。
- dhfr/dhps六重突变体51I/59R/108N+436A/437G/613S:10%。
临床怎么用
- 作者认为需临床结局研究确认ACT疗效未受损。
- 作者认为需监测磺胺多辛-乙胺嘧啶耐药及581G出现。
- 作者认为塞内加尔需继续开展抗疟药耐药监测。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Since 2006, artemisinin-based combination therapies (ACTs) have been introduced in Senegal in response to chloroquine resistance (CQ-R) and have shown high efficacy against Plasmodium falciparum. However, the detection of the PfKelch13R515K mutation in Kaolack, which confers artemisinin resistance in vitro, highlights the urgency of strengthening antimalarial drug surveillance to achieve malaria elimination by 2030. OBJECTIVE: To assess the proportion of P. falciparum parasites carrying molecular signatures associated with antimalarial resistance (PfKelch13, Pfmdr1, Pfcrt, dhfr and dhps) in isolates collected at Kédougou using multiplex amplicon deep sequencing. METHODS: Venous blood samples were collected from patients diagnosed with P. falciparum infection over a 3-year period (2021, 2022 and 2023). Parasite DNA was extracted, and multiplex amplicon sequencing was used to investigate gene polymorphisms. RESULTS: Analysis of PfKelch13 did not reveal any non-synonymous mutations. Pfcrt mutations were present in 45% of the samples, mainly K76T (44%) and I356T (36%). The dominant Pfmdr-1 allele was Y184F (62%). The sextuple mutant 51I/59R/108N + 436A/437G/613S dhfr/dhps was observed in 10% of the samples. CONCLUSION: The absence of PfKelch13 mutants suggests that ACT efficacy remains uncompromised, although clinical outcome studies are required to confirm this. Analysis of Pfcrt and Pfmdr-1 shows that CQ-R alleles, probably from previous CQ use, are slowly decreasing. Likewise, the detection of the dhfr/dhps sextuple mutant highlights the need to monitor sulfadoxine-pyrimethamine resistance and the emergence of 581G. There is therefore a need for continued antimalarial resistance surveillance in Senegal.
引用
- Wade A, Sene SD, Caspar E, et al. Monitoring molecular markers associated with antimalarial drug resistance in south-east Senegal from 2021 to 2023. J Antimicrob Chemother. 2025. PMID: 39846779. doi:10.1093/jac/dkaf006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。